Subscribe to our Newsletters !!
The safety and quality of produced medicines is ex
The use of the Greek letter sigma (Σ, σ) extends
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
2026 marks a new chapter for the pharmaceutical an
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-look
Siberia’s Vector virology institute on September 8 finished early-stage human trials, called Phase II, of a second possible Russian vaccine against COVID-19, the state consumer safety watchdog was cited by the Interfax news agency as saying.
Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya Institute, in August after finishing early-stage human trials.
“Today… the last group of 20 volunteers was released from hospital,” watchdog Rospotrebnadzor said in a statement.
“All 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling great.”
